10.1093/oxfordjournals.bmb.a072259 33 EyreD
Disclaimer: All references to research subjects or test subjects or any reference to research throughout this article refer to research conducted on non-human non-veterinary research subjects such as rats and mice
As with all GLP-1 therapies, there are important safety considerations: Not suitable for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) May cause nausea, vomiting, diarrhea , especially during dose titration Monitor for signs of pancreatitis , gallbladder issues, or allergic reactions Not indicated for patients with Type 1 diabetes or those with severe gastrointestinal disorders Regular follow-ups, lab monitoring, and dose adjustments are part of the DrWell Methodology to ensure safe, effective outcomes
Common side effects include headaches, dry mouth, sickness, dizziness, stomach pain and diarrhoea
Pickart, L., Margolina, A
Performed data analysis : Phillip M
